id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263031-cco2vh0f	Vultaggio, Alessandra	Considerations on Biologicals for Patients with allergic disease in times of the COVID‐19 pandemic: an EAACI Statement	2020-06-05		.txt	text/plain	2870	177	41	We discuss immunological and clinical considerations for patients on biologic agents (biologicals)targeting the type 2 inflammatory response due to difficult-to-treat allergic diseases in the context of COVID-19. In other coronavirus infections such as severe acute respiratory syndrome (SARS), type I IFN are critical for the initiation of immune response and virus clearance. In line with a paucity of mechanistic data on COVID-19 in the context of type 2 inflammation, knowledge on the disease course in patients treated with biologicals targeting type 2 inflammation due to severe asthma or other atopic diseases, such as CSU, AD and CRSwNP, is scarce to absent. In the past years, new biological therapies for severe asthma, atopic dermatitis (AD), chronicrhinosinusitis with nasal polyps (CRSwNP) and chronic spontaneous urticaria (CSU) have been developed targeting different aspects of the type 2 immune response.	./cache/cord-263031-cco2vh0f.txt	./txt/cord-263031-cco2vh0f.txt